Protein kinases are important regulators of cellular proliferation and several, such as HER-2/neu, and the epidermal growth factor receptor (EGFR), have been implicated in the pathogenesis and progression of human breast cancer. We have speculated that other kinases expressed in breast cancer cells may have important functions in the genesis or maintenance of the malignant state. For this reason, we have completed a search for novel kinases in breast cancer tissue and have identified several potentially important species: Our work with the focal adhesion kinase (FAK) is among the more advanced subprojects. We have found that FAK expression is correlated with the invasive and metastatic phenotype and thus may represent a useful marker in early stage breast cancer. Moreover, specific attenuation of FAK expression by antisense oligonucleotides induces apoptosis in cancer cell lines making FAK a rational target for gene directed therapeutics. rak is a src related tyrosine kinase with a nuclear localization signal within its SH2 domain, rak is a unique nuclear tyrosine kinase that binds to the retinoblastoma gene protein, Rb, through its SH3 domain. This implicates rak in cell cycle control and potentially in transformation. STK1 is the human homolog of the cdc2 activating kinase (CAK) which is essential for cdc2/cyclin function. Our investigations show that inhibition of CAK expression results in attenuation of growth in a breast cancer cell line. TK5 is a new JAK kinase, JAK3, expressed in primary breast cancer cells and cell lines, and which is also the important kinase partner for the IL-2/IL-4 receptor. Our discovery of different splice forms with one leading to an enzymatically inactive JAK3 kinase suggests complex signalling through potentially novel cytokine receptors. In this proposal we will focus upon FAK, rak and CAK, characterizing the role of these novel species in breast cancer biology especially in growth and differentiation and to using this knowledge in the design of more specific and directed therapies for breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-07
Application #
6102858
Study Section
Project Start
1998-08-05
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Butler, Eboneé N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Echavarria, Isabel; López-Tarruella, Sara; Picornell, Antoni et al. (2018) Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 24:1845-1852

Showing the most recent 10 out of 598 publications